Helena Back
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Helena Back has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Anders Tegnell
Public Health Agency of Sweden, Stockholm, Sweden
1 shared publication - Bernice Aronsson
Licensing Division, Swedish Medical Products Agency, Uppsala, Sweden
1 shared publication - Björn Zethelius
Use and Information Division, Swedish Medical Products Agency, Uppsala, Sweden
1 shared publication - Johanna Rubin
Public Health Agency of Sweden, Stockholm, Sweden; and Division of Paediatrics, Department of Clinical Science, Technology and Intervention, Karolinska Institutet, Stockholm, Sweden
1 shared publication - Johnny Ludvigsson
Division of Pediatrics, Department of Biomedical and Clinical Sciences, Linköping University
1 shared publication - Nicklas Pihlström
Pharmacoepidemiology and Analyses Department, Swedish Medical Products Agency, 75103, Uppsala, Sweden
1 shared publication
Latest Publications
- Open Access
- 16 October 2025
- Published by Uppsala Medical Society in Upsala Journal of Medical Sciences
- Vol. 130, e12937
Overview of approved COVID-19 vaccines in the EU, recommendations for use in Sweden and vaccine uptake over time
Objective: The aim of this review is to describe the regulatory background of the COVID-19 vaccines, the national recommendations for use issued and vaccine uptake in Sweden. It includes an overview of licensing and relevant safety aspects identified by the European Medicines Agency (EMA) and the national vaccination plan issued by the Public Health Agency (PHA) of Sweden. Materials and methods: Information on dates of licensing and safety aspects of importance identified by EMA published on its website, was compiled and presented in a chronological order. National recommendations on COVID-19-vaccination and vaccinations-data on uptake and coverage using the national-vaccine-register are presented. Results: COVID-19 vaccines development, assessments using rolling review and licensing of the covid-19 vaccines was done in 2020 during less than a year. Large-scale production was implemented. Monthly safety reviews performed by the EMA identified risk for thrombosis with thrombocytopenia syndrome with adenoviral vaccines and myocarditis for mRNA vaccines which led to restrictions in national recommendations for specified groups. National vaccinations were launched in a phased manner during 2021. Persons of high age, risk groups and nursing home personnel were prioritised during primary vaccinations and for initial boosters. In the Swedish population, 85% recieved at least on vaccine dose from the age of 12. At least two doses were recieved by 81% from age 18 and 95% from age 80. Conclusion: Recommendations for national use adhered to relevant adverse drug reactions identified. The vaccine coverage was high. Timelines presented should be considered in follow-up studies of COVID-19-vaccines to manage possible selection bias and confounding.
- 16 October 2025
- Published by Uppsala Medical Society in Upsala Journal of Medical Sciences
- Vol. 130, e12937
Open AccessOverview of approved COVID-19 vaccines in the EU, recommendations for use in Sweden and vaccine uptake over time
Objective: The aim of this review is to describe the regulatory background of the COVID-19 vaccines, the national recommendations for use issued and vaccine uptake in Sweden. It includes an overview of licensing and relevant safety aspects identified by the European Medicines Agency (EMA) and the national vaccination plan issued by the Public Health Agency (PHA) of Sweden. Materials and methods: Information on dates of licensing and safety aspects of importance identified by EMA published on its website, was compiled and presented in a chronological order. National recommendations on COVID-19-vaccination and vaccinations-data on uptake and coverage using the national-vaccine-register are presented. Results: COVID-19 vaccines development, assessments using rolling review and licensing of the covid-19 vaccines was done in 2020 during less than a year. Large-scale production was implemented. Monthly safety reviews performed by the EMA identified risk for thrombosis with thrombocytopenia syndrome with adenoviral vaccines and myocarditis for mRNA vaccines which led to restrictions in national recommendations for specified groups. National vaccinations were launched in a phased manner during 2021. Persons of high age, risk groups and nursing home personnel were prioritised during primary vaccinations and for initial boosters. In the Swedish population, 85% recieved at least on vaccine dose from the age of 12. At least two doses were recieved by 81% from age 18 and 95% from age 80. Conclusion: Recommendations for national use adhered to relevant adverse drug reactions identified. The vaccine coverage was high. Timelines presented should be considered in follow-up studies of COVID-19-vaccines to manage possible selection bias and confounding.